Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials

Abstract Background Immunotherapies, specifically those based on immune checkpoint inhibitors, have shown promising activity in multiple tumor types. Other than mifamurtide (MEPACT®) for osteosarcoma approved by European Medicines Agency, there are no approved immunotherapies for sarcomas. Methods W...

Full description

Bibliographic Details
Main Authors: Roman Groisberg, David S. Hong, Amini Behrang, Kenneth Hess, Filip Janku, Sarina Piha-Paul, Aung Naing, Siqing Fu, Robert Benjamin, Shreyaskumar Patel, Neeta Somaiah, Anthony Conley, Funda Meric-Bernstam, Vivek Subbiah
Format: Article
Language:English
Published: BMJ Publishing Group 2017-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Sarcoma
Immunotherapy
Checkpoint inhibitor
Phase 1
Anti-PD-1
Anti-PD-L1
Online Access:http://link.springer.com/article/10.1186/s40425-017-0301-y

Internet

http://link.springer.com/article/10.1186/s40425-017-0301-y

Similar Items